Nobex has been awarded two patents for technology related to its ambition to transform injectable-only drugs into ones that can be delivered orally.
The patents are centered around medicinal chemistry. One of the targets for Nobex is an oral insulin drug that would consist of a tablet dosage.
“The two new patents — can enable or enhance the delivery of both
peptide-based and small organic molecules by oral delivery but also by other routes of administration including injection, pulmonary and transdermal delivery,” Nobex said in a statement.
Nobex: www.nobexcorp.com
